Qinglin Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qinglin Li has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Zhong-Yin Zhang
James Tarpo Jr. and Margaret Tarpo Department of Chemistry Purdue University 560 Oval Drive West Lafayette Indiana 47907 USA
31 shared publications - Frederick Nguele Meke
Borch Department of Medicinal Chemistry and Molecular Pharmacology
30 shared publications - Yunpeng Bai
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A.
30 shared publications - Colin Carlock
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana
29 shared publications - Diego Ruiz-Avila
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana
29 shared publications - Jinan Ayub
Indiana University School of Medicine
29 shared publications
Latest Publications
- Open Access
- 10 April 2025
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 482  (07) , 341-356
The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor
The phosphatases of regenerating liver (PRLs) are members of the protein tyrosine phosphatase (PTP) superfamily that play pro-oncogenic roles in cell proliferation, migration, and survival. We previously demonstrated that PRLs can post-translationally down-regulate PTEN, a tumor suppressor frequently inactivated in human cancers, by dephosphorylating PTEN at Tyr336, which promotes the NEDD4-mediated PTEN ubiquitination and proteasomal degradation. Here, we report that PRLs can also reduce PTEN expression by up-regulating microRNA-21 (miR-21), which is one of the most frequently overexpressed miRNAs in solid tumors. We observe a broad correlation between PRL and miR-21 levels in multiple human cancers. Mechanistically, PRL2, the most abundant and ubiquitously expressed PRL family member, promotes the JAK2/STAT3 pathway-mediated miR-21 expression by directly dephosphorylating JAK2 at Tyr570. Finally, we confirm that the PRL2-mediated miR-21 expression contributes to its oncogenic potential in breast cancer cells. Our study defines a new functional role of PRL2 in PTEN regulation through a miR-21-dependent post-transcriptional mechanism, in addition to our previously reported NEDD4-dependent post-translational PTEN regulation. Together, these studies further establish the PRLs as negative regulators of PTEN.
- 10 April 2025
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 482  (07) , 341-356
Open AccessThe PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor
The phosphatases of regenerating liver (PRLs) are members of the protein tyrosine phosphatase (PTP) superfamily that play pro-oncogenic roles in cell proliferation, migration, and survival. We previously demonstrated that PRLs can post-translationally down-regulate PTEN, a tumor suppressor frequently inactivated in human cancers, by dephosphorylating PTEN at Tyr336, which promotes the NEDD4-mediated PTEN ubiquitination and proteasomal degradation. Here, we report that PRLs can also reduce PTEN expression by up-regulating microRNA-21 (miR-21), which is one of the most frequently overexpressed miRNAs in solid tumors. We observe a broad correlation between PRL and miR-21 levels in multiple human cancers. Mechanistically, PRL2, the most abundant and ubiquitously expressed PRL family member, promotes the JAK2/STAT3 pathway-mediated miR-21 expression by directly dephosphorylating JAK2 at Tyr570. Finally, we confirm that the PRL2-mediated miR-21 expression contributes to its oncogenic potential in breast cancer cells. Our study defines a new functional role of PRL2 in PTEN regulation through a miR-21-dependent post-transcriptional mechanism, in addition to our previously reported NEDD4-dependent post-translational PTEN regulation. Together, these studies further establish the PRLs as negative regulators of PTEN.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in Tp53 heterozygous mice
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion upregulates PTEN to inhibit Akt signaling and hinder tumor cell proliferation in inducible Tp53−/− mice. A, Representative Western blot analysis from inducible Tp53−/− and inducible Tp53−/−; Prl2−/−–derived thymic lymphomas to determine expression of PTEN, PUMA, BAX, p21, cyclin D1, p27, as well as the expression and activation of Akt and Akt targets. The actin loading control shown is the same as that in Fig. 4A. B, Dot plot for quantification of PTEN and Akt activation. C, Dot plot for quantification of Western blot analysis for the activation of Akt targets mTOR and GSK3β. D, Dot plot for quantification of the expression of Tp53 targets PUMA, BAX, p21, and cyclin D1. E, Dot plot for quantification of FoxOs activation and p27 expression. Data shown as mean ± SEM for samples obtained 12 weeks after tamoxifen treatment, Tp53−/− n = 10–20, Tp53−/−; Prl2−/− n = 10–14; *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Experiemental design for tamoxifen inducible Tp53 deletion w/o Prl2 deletion
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Experiemental design for tamoxifen inducible Tp53 deletion w/o Prl2 deletion
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion enhances survival and hinders tumor growth rate in tamoxifen-inducible Tp53−/− mouse but does not affect tumor initiation. A, PCR genotyping to identify different genotypes in the study. B, Kaplan–Meier survival plot for thymic lymphoma-free survival in tamoxifen-inducible Tp53−/− n = 43 and inducible Tp53−/−; Prl2−/− n = 33. C, Bar graph representing percent tumor incidence in inducible Tp53−/− background with or without inducible Prl2 deletion. Dot plots representing: The mass of thymus/thymic lymphoma over time in inducible Tp53−/− n = 9–20 per timepoint and inducible Tp53−/−; Prl2−/− n = 8–14 per timepoint (D). E, Thymocyte population ratios 9 weeks after inducing Tp53 deletion with or without Prl2 deletion. F, Thymocyte population ratios 12 weeks after inducing Tp53 deletion with or without Prl2 deletion. DP: Double positive (CD4+ CD8+). DN: Double negative (CD4− CD8−). log-rank test performed for Kaplan–Meier survival curves and Student t test performed for all other analysis. Data are shown as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion does not affect Erk activation in inducible Tp53-/- mice derived thymic lymphomas
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion does not affect Erk activation in inducible Tp53-/- mice derived thymic lymphomas
- Open Access
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations
- 2 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models
Prl2 deletion inhibits tumor cell proliferations